Challenges of Estimating Fracture Risk with DXA: Changing Concepts About Bone Strength and Bone Density.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Aerospace Medicine and Human Performance

• Publication date

  2015-07-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.3357/AMHP.4208.2015PMID 26102143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differing effects of denosumab and alendronate on cortical and trabecular bone.

  2014cited by this paper
• Magnitude of fragility fracture risk in the very old—are we meeting their needs? The Newcastle 85+ Study

  2014cited by this paper
• Skeletal health in long‐duration astronauts: Nature, assessment, and management recommendations from the NASA bone summit

  2013cited by this paper
• In Obese Postmenopausal Women, Bone Microarchitecture and Strength Are Not Commensurate to Greater Body Weight: The Os des Femmes de Lyon (OFELY) Study

  2013cited by this paper
• DXA parameters: beyond bone mineral density.

  2013cited by this paper
• Diabetes and femoral neck strength: findings from the Hip Strength Across the Menopausal Transition Study.

  2012cited by this paper
• Assessment of bone quality and strength with new technologies

  2012cited by this paper
• Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls

  2012cited by this paper
• Differences in structural geometrical outcomes at the neck of the proximal femur using two-dimensional DXA-derived projection (APEX) and three-dimensional QCT-derived (BIT QCT) techniques

  2012cited by this paper
• Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis.

  2011cited by this paper
• Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae.

  2011cited by this paper
• Bone structure and density via HR-pQCT in 60d bed-rest, 2-years recovery with and without countermeasures.

  2011cited by this paper
• An in vivo comparison of hip structure analysis (HSA) with measurements obtained by QCT

  2011cited by this paper
• Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: The manitoba study

  2011cited by this paper
• Bone metabolism and fracture risk in type 2 diabetes mellitus [Review].

  2011cited by this paper
• In vivo discrimination of hip fracture with quantitative computed tomography: Results from the prospective European Femur Fracture Study (EFFECT)

  2011cited by this paper
• Mineral maturity and crystallinity index are distinct characteristics of bone mineral

  2010cited by this paper
• Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus

  2010cited by this paper
• A Retrospective Case–Control Study Assessing the Role of Trabecular Bone Score in Postmenopausal Caucasian Women with Osteopenia: Analyzing the Odds of Vertebral Fracture

  2010cited by this paper
• Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

  2009cited by this paper
• Selective Modification of Bone Quality by PTH, Pamidronate, or Raloxifene

  2009cited by this paper
• Development and Validation of a Predictive Bone Fracture Risk Model for Astronauts

  2009cited by this paper
• Age-Dependence of Femoral Strength in White Women and Men

  2009cited by this paper
• Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study.

  2009cited by this paper
• Osteopetrosis

  2009cited by this paper
• Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density

  2009cited by this paper
• Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method

  2009cited by this paper
• Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies

  2008cited by this paper
• Biomarkers for Osteoporosis Management

  2008cited by this paper
• National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.

  2008cited by this paper
• Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial

  2006cited by this paper
• Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT.

  2006cited by this paper
• The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.

  2006cited by this paper
• Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.

  2006cited by this paper
• Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis

  2006cited by this paper
• Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.

  2005cited by this paper
• Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.

  2004cited by this paper
• Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.

  2004cited by this paper
• Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis

  2004cited by this paper
• Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.

  2004cited by this paper
• Risedronate Preserves Bone Architecture in Early Postmenopausal Women In 1 Year as Measured by Three-Dimensional Microcomputed Tomography

  2003cited by this paper
• Fluorides and osteoporosis.

  2003cited by this paper
• Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

  2002cited by this paper
• Mechanical strength of the thoracolumbar spine in the elderly: prediction from in situ dual-energy X-ray absorptiometry, quantitative computed tomography (QCT), upper and lower limb peripheral QCT, and quantitative ultrasound.

  2002cited by this paper
• Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density

  2002cited by this paper
• Improving Risk Assessment: Hip Geometry, Bone Mineral Distribution and Bone Strength in Hip Fracture Cases and Controls. The EPOS Study

  2002cited by this paper
• Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

  2002cited by this paper
• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

  2000cited by this paper
• Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

  2000cited by this paper
• Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

  2000cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• Femoral strength is better predicted by finite element models than QCT and DXA.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Early Changes in Biochemical Markers of Bone Turnover Predict the Long‐Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial

  1998cited by this paper
• Age and bone mass as predictors of fracture in a prospective study.

  1988cited by this paper
• Assessment of bone mineral. Part 2.

  1984cited by this paper

• How Accurately Does Bone Mineral Density Predict Bone Strength? A Clinical Observational Study of Osteoporosis Vertebral Compression Fractures in Postmenopausal Women

  2025cites this paper
• [18F]NaF PET/CT Imaging of Iliac Bones to Assess Bone Turnover

  2025cites this paper
• Effect of Collagen Peptide, Alone and in Combination with Calcium Citrate, on Bone Loss in Tail-Suspended Rats

  2020cites this paper
• Diagnosis and Monitoring of Osteoporosis with Total-Body 18F-Sodium Fluoride-PET/CT.

  2020cites this paper
• Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management

  2019cites this paper
• Study of human radius construction systematics: evaluation by DXA in dry bone

  2018cites this paper
• Forecasting post-flight hip fracture probability using probabilistic modeling.

  2018cites this paper